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Abstract Immune activated T lymphocytes modulate the activity of key metabolic pathways to
support the transcriptional reprograming and reshaping of cell proteomes that permits effector T
cell differentiation. The present study uses high resolution mass spectrometry and metabolic
labelling to explore how murine T cells control the methionine cycle to produce methyl donors for
protein and nucleotide methylations. We show that antigen receptor engagement controls flux
through the methionine cycle and RNA and histone methylations. We establish that the main rate
limiting step for protein synthesis and the methionine cycle is control of methionine transporter
expression. Only T cells that respond to antigen to upregulate and sustain methionine transport are
supplied with methyl donors that permit the dynamic nucleotide methylations and epigenetic
reprogramming that drives T cell differentiation. These data highlight how the regulation of
methionine transport licenses use of methionine for multiple fundamental processes that drive T
lymphocyte proliferation and differentiation.
DOI: https://doi.org/10.7554/eLife.44210.001
Introduction
T lymphocytes responding to antigen undergo rapid proliferation as they differentiate to produce
effector populations. T cells also undergo large-scale, dynamic transcriptional remodelling during
differentiation in response to immune activation (Sen et al., 2016; Crompton et al., 2016;
Gray et al., 2014; Zhang et al., 2014). Immune activation of T lymphocytes requires that these cells
adapt their metabolic programs to support rapid clonal expansion and cell differentiation. For exam-
ple, activated T cells accelerate glucose metabolism to fuel oxidative phosphorylation, glycolysis and
the production of UDP-GlcNAc to allow critical intracellular protein O-GlcNAcylations (Donnelly and
Finlay, 2015; Swamy et al., 2016). Activated T cells also dramatically upregulate lipid production
programs to meet the demand for membrane biosynthesis associated with growth and
proliferation (Kidani et al., 2013). T cells also need a supply of glucose, leucine and arginine to sus-
tain the activity of the serine/threonine kinase complex Mammalian Target of Rapamycin Complex 1
(mTORC1) (Finlay et al., 2012; Nicklin et al., 2009; Wang et al., 2015), a critical kinase that regu-
lates the differentiation and migratory capacity of effector T cells (Delgoffe et al., 2011;
Sinclair et al., 2008); serine is required for biosynthesis of purine nucleotides needed for T cell pro-
liferation (Ma et al., 2017).
It is thus increasingly recognised that ensuring that T cells have a sufficient supply of metabolic
substrates for key biological processes is critical for T cell participation in adaptive immune
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responses. Hence understanding how the supply of these substrates is controlled is essential. In this
context, it is evident that protein and nucleotide methylations are essential for T cell differentiation:
Histone and DNA methylations are key epigenetic modifications that control the accessibility of
DNA to the transcriptional machinery (Allis and Jenuwein, 2016). The methylation of RNA is also
critical for cell function: mRNA cap methylation controls mRNA binding to the eukaryotic translation
initiation factor 4E (eIF4E) to regulate translation initiation (Aregger and Cowling, 2017; Gonato-
poulos-Pournatzis and Cowling, 2014; Varshney et al., 2018); the methylation of adenosine,
‘m6A’, in RNA controls multiple processes including translation, splicing and stability of mRNA
(Dominissini et al., 2012; Louloupi et al., 2018; Li et al., 2017; Mauer et al., 2017). Furthermore,
there is an increasing awareness that protein arginine methylation is critical for T lymphocyte activa-
tion (Inoue et al., 2018). How do T cells ‘manage’ the increased demand for methyl donors as they
respond to immune activation? In this context, methionine is an essential amino acid in mammals for
de novo protein synthesis but it is also required for the production of S-adenosylmethionine (SAM),
the universal methyl donor for DNA, RNA and protein methyltransferases. The unanswered question
then is how is methionine metabolism and the production of methyl donors controlled in T cells?
There are many studies showing the importance of protein, RNA, DNA and histone methyltransfer-
ases in T cells (Inoue et al., 2018; Li et al., 2017; Lee et al., 2001; Thomas et al., 2012;
Yang et al., 2015; Karantanos et al., 2016; Gray et al., 2017; Sellars et al., 2015; DuPage et al.,
2015; Geoghegan et al., 2015; Zhang et al., 2014; Tumes et al., 2013; Gamper et al., 2009).
However, critical facts about methionine metabolism are unknown; do naı¨ve T cells express all the
key enzymes for methionine metabolism to provide methyl donors for methyltransferases? Is there
any immune regulation of flux through the methionine cycle? It is also unknown how T cells control
intracellular methionine availability in terms of the balance between the production of methionine
from intracellular recycling (salvage pathways) versus external sources. How dependent is T cell acti-
vation on the external methionine supply? What are the relevant methionine transporters in T
eLife digest White blood cells known as T cells are an essential part of the immune system. If
these cells do not work properly the immune system falls down, leading to disease and eventually
death. T cells have receptors on their surface that can detect molecules that do not belong in the
body and that may indicate an infection or cancer. When one of these foreign molecules is detected,
the T cell will activate and transform to become better equipped to protect the body. These two
processes known as activation and differentiation involve extensive changes within the T cell. Many
of these changes rely on the addition of a small chemical tag onto molecules such as DNA, RNA or
proteins. The tag, a methyl group, is most often obtained by breaking down a chemical called
methionine, one of the building blocks of proteins.
Like all other animals, humans cannot make methionine, and so we must instead obtain it through
our diet or recycle it from existing proteins. This raised some questions: does the availability of
methionine limit the activity of T cells? And, if so, is it the uptake or breakdown of methionine that
has the biggest effect?
Sinclair et al. answered these questions by studying T cells from mice. First, the T cells were
activated, the proteins from those cells were then collected and quantified using a technique called
high resolution mass spectrometry.
In further experiments, the uptake and use of a radioactively labeled version of methionine was
followed in activated T cells. Using these approaches, Sinclair et al. showed T cell activation
increased the cells demand for methionine, and that T cells need a steady supply of methionine to
remain activated. The main limiting factor in this process was the speed at which the cell could make
the transport systems it needs to collect methionine from its surroundings.
These findings could prove useful in developing treatments for diseases associated with
uncontrollable T cells, such as leukaemia and certain autoimmune diseases. Such treatments could,
for example, involve restricting the transport of methionine into T cells through drugs, or potentially
via the diet.
DOI: https://doi.org/10.7554/eLife.44210.002
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lymphocytes and is methionine metabolism coupled to T cell activation and differentiation into effec-
tor cells?
The present study uses high resolution mass spectrometry and metabolic labelling strategies to
address these fundamental questions. The data identify and quantify expression of the key enzymes
of the methionine cycle in T cells and document how these are regulated by immune activation. Key
observations are that methionine flux through the methionine cycle is controlled by the T cell antigen
receptor and that a constant sustained external supply of methionine is necessary for T cell immune
activation to sustain protein biogenesis, histone methylation and RNA methylation. We identify a
dominant rate limiting step for the production of methyl donors for nucleotide and protein methyla-
tions in immune activated T cells is methionine transport across the T cell membrane. Antigen recep-
tor regulation of methionine transport across the cell membrane is thus a key step that licenses the
use of methionine for fundamental cellular process that drive T lymphocyte proliferation and
differentiation.
Results
The sustained supply of extracellular methionine is important for
activation of T cells
To investigate whether methionine availability in the external environment is important for T cells,
we initially assessed the impact of methionine deprivation on the immune activation of CD4+ T cells.
Flow cytometric forward and side scatter analysis of CD4+ T cells activated in the absence of methio-
nine revealed that these cells do not undergo normal cell growth/blastogenesis (Figure 1a). TCR-
activated CD4+ T cells deprived of methionine are smaller than CD4+ T cells activated in the pres-
ence of methionine (Figure 1a), and fail to proliferate (Figure 1b). However activation markers such
as CD69 are expressed normally (Figure 1c). Methionine levels in RPMI tissue culture media are 100
mM. Serum methionine availability has been shown to range from 3 to 30 mM (Mentch et al., 2015),
consequently we used levels of methionine spanning this range to further explore the importance of
extracellular methionine availability for CD4+ T cell differentiation. In these experiments CD4+ T cells
were activated by triggering TCR complexes and CD28 and cultured in Interleukin 2 (IL2) and IL12 to
differentiate into Th1 cells that produce high levels of interferon gamma (IFNg). We assessed the
impact of restricting methionine availability on CD4+ T cell differentiation by activating the cells in
media with different levels of methionine. The data in Figure 1d show that the frequency of IFNg
producing CD4+ T cells is dependent upon extracellular methionine availability (Figure 1d). A 2-fold
reduction in methionine from 10 mM to 5 mM thus had a striking impact on the frequency of IFNg
producing CD4+ T cells that could develop under Th1 polarising conditions (Figure 1e) and also con-
trolled the amount of IFNg produced per cell (Figure 1f).
These initial experiments show that methionine availability is rate limiting for T cell activation and
differentiation. However, another question is how important is sustained methionine supply for T cell
function? To address this question T cells were activated through TCR/CD28 in a saturating concen-
tration of external methionine (100 mM) for 20 hr prior to culturing in reduced concentrations of
methionine for a further 2 hr. We then used quantitative single cell assays to assess the impact of
acute restriction of methionine availability for protein synthesis, RNA and DNA synthesis in immune
activated T cells. Protein synthesis was assayed using a single cell assay that quantifies the incorpo-
ration of an analogue of puromycin into nascent protein chains in the ribosome; total RNA and DNA
synthesis were measured by monitoring incorporation of the nucleoside analogue, 5-ethynyl uridine
(EU) or a modified thymidine analogue (EdU) respectively. The data show that T cells activated in the
presence of 100 mM methionine have high rates of protein, RNA and DNA synthesis (Figure 1g–i).
However, limiting extracellular methionine availability for 2 hr strikingly impacted on the ability of
the cells to maintain these key processes. The EC50, that is the concentration of methionine required
for half maximal effect was in these TCR/CD28 activated CD4+ cells was 1.39 mM for protein synthe-
sis; 2.94 mM for RNA synthesis and 12.62 mM for the frequency of cells undergoing DNA synthesis
(Figure 1j–l). Similar experiments were done with Th1 effector cells. These were differentiated for 5
days in 100 mM methionine and then maintained for five hours in methionine limited media. The
data show that the ability of Th1 cells to sustain RNA, protein and DNA synthesis is also dependent
on sustained methionine supply (Figure 1m–o).
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Figure 1. T cell activation and differentiation requires a sustained supply of extracellular methionine. (a) Flow cytometry plots show the forward (FSC)
and side (SSC) scatter profiles of CD4+ T cells stimulated through the TCR (CD3/CD28) for 18 hr ± methionine. (b) Cell counts of CD4+ T cells over 48 hr
after TCR-stimulation (CD3/CD28) in the presence or absence of methionine. (c) Flow cytometry plots CD69 expression of CD4+ T cells stimulated
through the TCR (CD3/CD28) for 18 hr ± methionine. (d-f) CD4+ T cells activated with CD3/CD28 antibodies + IL2/IL12 for 3 days in indicated
Figure 1 continued on next page
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Methionine metabolic pathways in T cells.
Methionine is the predominant ‘start’ amino acid used to initiate polypeptide synthesis during
mRNA translation. Figure 2a shows naı¨ve CD4+ T cells have almost undetectable incorporation of
extracellular 3H-methionine into protein, however incorporation of 3H-methionine into protein is
greatly increased upon activation through the TCR (Figure 2a).
One explanation for the environmental methionine requirement for T cells is that it fuels protein
synthesis. However methionine fuels other essential metabolic pathways, consequently we used
mass spectrometry to explore methionine metabolism in CD4+ T cells stimulated via the T cell anti-
gen receptor/CD28 complex. In particular, the methionine cycle which is initiated when methionine
is converted into S-adenosylmethionine (SAM) in an ATP-consuming reaction and catalysed by
methionine adenosyltransferase (MAT2A). Methyltransferases then transfer the methyl group from
SAM to yield S-adenosylhomocysteine (SAH) and a methylated substrate. SAH is swiftly converted
into homocysteine (HCy) by S-adenosylhomocysteine hydrolase (AHCY, also known as SAHH). The T
cell metabolomics data show that SAM levels remain relatively constant between TCR stimulated
and naı¨ve CD4+ T cells (Figure 2b). However, TCR activated cells show an increase in the generation
of S-adenosylhomocysteine (SAH) and HCy (Figure 2b). This increased production of SAH and HCy
demonstrates that triggering the TCR drives increased flow through the methionine cycle. HCy has
two potential metabolic fates, that is, it can be converted to cystathionine, or recycled back into
methionine via subsequent enzymatic reactions through the de novo pathway. In the de novo path-
way, methionine synthase (MTR) and the cofactor vitamin B12 perform the rate-limiting step of incor-
porating methyl groups derived from folate metabolism and HCy to produce methionine. SAM can
also be utilised for polyamine synthesis, providing spermine and spermidine and yielding 5-methyl-
thioadenosine (MTA). The sulphur of MTA can be recycled back into methionine using the salvage
pathway, the first step of which is catalysed by MTA phosphorylase (MTAP) to generate 5-methyl-
thioribose-1-phosphate (reviewed in Mentch and Locasale, 2016; Albers, 2009). In this context, fur-
ther evidence that TCR triggering drives the methionine cycle is provided by the data showing that
activated CD4+ T cells accumulate 5-methylthioadenosine (MTA) and Methyl-5-thio-5-D-ribose 1-
phosphate; metabolites produced downstream of polyamine synthesis. Activated CD4+ T cells also
had increased levels of cystathionine and 2-oxobutanoate (C4H6O3); the latter is produced when
cystathionine gamma-lyase converts cystathionine to cysteine (Figure 2b).
One function for the methionine metabolite, S-adenosylmethionine (SAM), is as a methyl donor
for methylation modification reactions. The increased production of S-adenosylhomocysteine (SAH)
in TCR activated cells argues that SAM is being used as a methyl donor during T cell activation. To
explore links between TCR triggering and methylation pathways we first explored if activated T cells
showed increased protein methylation by monitoring the methylation status of histone H3 at both
activating (lysine 4; H3K4) and inhibitory (lysine 27; H3K27) sites. To investigate the methylation sta-
tus of H3K4 and H3K27 in CD4+ T cells we used flow cytometry with antibodies that recognise trime-
thylation on H3K4 and H3K27, respectively. These experiments show that trimethylation (me3) of
both H3K4 and H3K27 in CD4+ T cells is increased upon in vitro TCR- stimulation (Figure 2c).
Figure 2d shows the ratio of staining of total H3, H3K27me3 and H3K4me3 of TCR-stimulated, com-
pared with non-stimulated CD4+ T cells (Figure 2d). We also addressed whether a similar increase in
Figure 1 continued
methionine concentrations. (d) CD44 surface staining and intracellular IFNg cytokine staining. The % CD4+ T cells producing IFNg is indicated on the
plot. The percentage (e) and MFI (f) of IFNg producing CD4+ T cells from three biological replicates. (g–l) CD4+ T cells were stimulated through the
TCR (CD3/CD28) for 20 hr before culturing in reducing concentrations of methionine for a further 2 hr. The histograms (left panel) show de novo protein
synthesis as measured by incorporation of the puromycin analog (OPP) (g) or RNA synthesis as determined by EU incorporation (h). The right panels
show the MFIs over the expanded dose response. Cyclohexamide (CHX) treatment or Actinomycin D (ActD) treatment are included as negative controls
for protein and RNA synthesis. (i) The histograms (left panel) show the frequency of CD4+ T cells undergoing DNA synthesis as measured by EdU
incorporation. The right panel shows the frequency of EdU positive cells over the expanded dose response. (j–l) EC50 values were calculated from dose
response curves (using logged concentration values). Goodness of fit is represented by the R2 values. (m–o) Th1 effector cells were expanded for 5 days
before culturing in reducing concentrations of methionine for a further 5 hr. The histograms show (m) de novo protein synthesis (n) RNA synthesis and
(o) DNA synthesis. (Plots are representative of 3 biological replicates. Gating strategies are provided in Supplementary file 1. Error bars are mean ± s.d
of: three biological replicates; Points on the graphs indicate biological replicates.).
DOI: https://doi.org/10.7554/eLife.44210.003
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Figure 2. Methionine metabolism in T cells. (a) 3H radioactivity measured in TCA precipitated protein from isolated CD4+ T cells stimulated through
the TCR (CD3/CD28) in the presence of 3H-methionine for the indicated times. (b) Metabolomic analysis of metabolites in the de novo pathway and the
salvage pathway of the methionine cycle. The graphs show metabolite intensity derived from integrated peak areas of MS intensity from naı¨ve CD4+ T
cells and TCR-stimulated CD4+ T cells (CD3/CD28, for 16 hr). Enzymes are indicated adjacent to arrows (in blue). P values are indicated on each graph.
Figure 2 continued on next page
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H3K27me3 and H3K4me3 occurs in vivo. Accordingly, CD4+ T cells from OT2 TCR transgenic mice
were adoptively transferred into normal hosts prior to immunisation with the cognate antigen, oval-
bumin. Analysis of the H3K27me3 and H3K4me3 staining shows that H3 trimethylation on K27 and
K4 increases upon immune activation in vivo (Figure 2e,f).
SAM is also used as a substrate for RNA methyltransferases, producing methylated RNA and
SAH. To investigate if there are changes in RNA methylation during T cell activation we designed
experiments where CD4+ T cells were activated in methionine-free media supplemented with 3H-
methionine where the radiolabel is attached to the methyl group. This allowed us to purify RNA
from the activated cells and quantified the incorporation of the 3H-methyl group into RNA. The data
show that the 3H-radiolabel is incorporated into RNA after 6 hr of TCR/CD28 stimulation, and this is
further increased after 18 hr (Figure 2g). A key control in this experiment is to ensure that there is
no protein contamination in the RNA extractions. For this we did a parallel quantification of the
incorporation of 3H-methionine and 3H-phenylalanine: the latter would only be present into cellular
proteins. The data show there was no protein contamination of these RNA preparations as judged
by absence of any detectable 3H-phenylalanine label, compared with high levels of 3H-phenylalanine
incorporated into protein (Figure 2h).
How dependent are these protein and nucleotide methylation reactions on extracellular methio-
nine? Figure 2i shows that SAH levels in TCR activated CD4+ T cells and Th1 cells are dependent
upon extracellular methionine supply which argues that sustained methionine availability is required
to produce methyl donors for protein and nucleotide methylation (Figure 2i). In this context, the
data in Figure 2j show that the increase in H3K4 and H3K27 trimethylation in CD4+ T cells in
response to TCR activation is regulated by extracellular methionine availability (Figure 2j). We also
examined the importance of extracellular methionine for RNA methylation in T cells. One of the
most abundant mammalian RNA modifications is methylation of the N6 adenosine (m6A) regulated
by the METTL3 methyltransferase (Liu et al., 2014a). This RNA methylation is important for mRNA
stability and in T cells has been shown to be essential for normal T cell function (Li et al., 2017). The
data in Figure 2k show that the percentage of total m6A methylation in effector Th1 cells decreases
as extracellular methionine is decreased (Figure 2k). Another RNA post-translational methyl modifi-
cation found in RNA is 5-methylcytosine (m5C), the data in Figure 2l show that the amount of m5C
in mRNA from effector Th1 cells is dependent upon extracellular methionine (Figure 2l). Collectively,
these data demonstrate that extracellular methionine is not only directed into protein synthesis in T
cells but also into the methionine cycle to generate methyl donors for histone and RNA methylation
Figure 2 continued
Source data is available in Figure 2—source data 1. (c) The histograms show representative intracellular staining of total H3, trimethylated H3K27
(H3K27me3) or trimethylated H3K4 (H3K4me3) from IL7 maintained (unstimulated) or TCR-stimulated (CD3/CD28) CD4+ T cells for 18 hr. Geometric
mean fluorescence intensities (MFI) are shown in the histograms. (d) The graph shows ratios of H3, H3K27me3 and H3K4me3 MFIs from TCR-stimulated
(CD3/CD28) CD4+ T cells compared to unstimulated CD4+ T cells. (e, f) OT2 (CD45.1) cells were adoptively transferred into WT CD45.2 hosts. The hosts
were immunised with NP-OVA/alum and the transferred OT2 cells were analysed after 3 days. The histograms (left) show representative intracellular
staining of H3K27me3 (e) and H3K4me3 (f). Graphs (right) show ratios of H3K27me3 and H3K4me3 MFIs in activated OT2 CD4+ T cells compared to
non-activated host CD4+ T cells 3 days post-immunisation. (g) 3H radioactivity measured in RNA extracted from isolated CD4+ T cells stimulated
through the TCR (CD3/CD28) in the presence of 3H-methionine for the indicated times. (h) 3H radioactivity measured in protein or RNA extracted from
CD4+ T cells stimulated in parallel to (g) in the presence 3H-phenylalanine for 18 hr. (i) Levels of SAH from unstimulated (naı¨ve cells), TCR-stimulated
(CD3/CD28, 18 hr) CD4+ T cells or IL2 maintained Th1 cells ± methionine for 18 hr. (j) The histograms show representative intracellular staining of total
H3, trimethylated H3K27 (H3K27me3) or trimethylated H3K4 (H3K4me3) from IL7 maintained (unstimulated) or TCR-stimulated (CD3/CD28) CD4+ T
cells±methionine as indicated (18 hr). (k) Percentage of RNA with m6A modification, as determined by ELISA, in Th1 cells cultured with decreasing
methionine concentrations for 5 hr (as indicated). (l) Percentage of RNA with m5C modification, as determined by ELISA, in Th1 cells
cultured ±methionine for 5 hr. (Error bars are mean ± s.d of: (a–d, i–l) three biological replicates (e–f) six biological replicates. (g,h) 4 (RNA) biological
replicates and five biological replicates (protein). MFIs are indicated in the histograms, points on the graphs indicate biological replicates. (b, e, l) t -
test; (d,i,k) One-way ANOVA; P= *<0.05, **<0.01, ***<0.001, ****<0.0001; Flow cytometry gating strategies are provided in Supplementary file 1).
DOI: https://doi.org/10.7554/eLife.44210.004
The following source data is available for figure 2:
Source data 1. Spreadsheet containing the list of metabolite intensities derived from integrated peak areas of MS intensity from naı¨ve CD4+ T cells
(N1-3) and TCR-stimulated CD4+ T cells (S1-3).
DOI: https://doi.org/10.7554/eLife.44210.005
Sinclair et al. eLife 2019;8:e44210. DOI: https://doi.org/10.7554/eLife.44210 7 of 29
Research article Immunology and Inflammation
reactions. Furthermore, the sustained supply of extracellular methionine is necessary for these
processes.
Methionine cycle regulation in T cells
The elevated levels of SAH and HCy and the increased levels of RNA and histone methylation dem-
onstrate that immune activated T cells increase metabolic flow through the methionine cycle. To
explore the molecular basis for the increases in methionine metabolism in activated T cells we used
quantitative, mass spectrometry-based proteomics to interrogate the expression and abundance lev-
els of methionine cycle enzymes in naı¨ve, TCR activated and effector CD4+ T cells. Critical enzymes
that regulate the metabolic flow through the two arms of the methionine cycle, the de novo and sal-
vage pathways, are shown in Figure 3a,b. We initially looked at the expression levels of these key
proteins in naı¨ve T cells by comparing their relative abundance against the backdrop of the total pro-
tein landscape. The data show that naı¨ve CD4+ T cells express the key methionine cycle enzymes
MAT2A, AHCY and MTR (Figure 3c,d and e). Interestingly, both MAT2A and AHCY are highly abun-
dant proteins in the naı¨ve cell proteomic landscape (Figure 3c and d). Similarly, SRM/SMS and
MTAP, enzymes which use SAM for polyamine synthesis and subsequent methionine salvage, are
abundantly expressed in naı¨ve T cells (Figure 3f and g). mtnA-D, enzymes involved in the final steps
of methionine salvage, are also expressed at levels higher than the ‘average’ protein is expressed in
a T cell (Figure 3h). The relative abundance, as indicated by their concentration, of these proteins
within the total proteomic landscape is consistently maintained at high levels upon activation and
differentiation of CD4+ T cells (Figure 3i).
The data in Figure 2 show that immune activation of T cells drives increased RNA methylation.
We therefore interrogated the proteomic data to quantify expression of essential RNA methyltrans-
ferases in naı¨ve and immune activated T cells. mRNA methyl cap formation marks RNAs for further
processing, nuclear export and translation initiation (Gonatopoulos-Pournatzis and Cowling, 2014);
the m6A RNA methylation regulates mRNA stability (Geula et al., 2015). Key methyltransferases for
RNA cap methylation are RNMT, the RNA (guanine-7-) methyltransferase (Cowling, 2009), and the
cap methyl transferases CMTR1 or CMTR2 (Inesta-Vaquera and Cowling, 2017). The proteomics
data show that RNMT and CMTR1 are abundantly expressed in naı¨ve and at similar levels in TCR
activated CD4+ T cells, whereas CMTR2 is not expressed at high levels in any population
(Figure 4a). The data show that naı¨ve T cells also express equimolar levels of the METTL3/METTL14
m6A methyltransferase complex (Figure 4b) (Liu et al., 2014b). Another frequent RNA modification
is cytosine  5 methylation (m5C). The proteomics data show that naı¨ve T cells express high levels of
NSUN2, the methyltransferase responsible for RNA m5C modification, these high levels are main-
tained after TCR activation and through differentiation (Figure 4c) (Yang et al., 2017).
The high levels of expression of the RNA methyl transferases in naı¨ve T cells is in contrast to the
pattern of expression of the histone and DNA methyl transferases. The expression of the DNA
methyl transferases DNMT1 and DNMT3a is markedly higher in immune activated CD4+ T cells than
in naı¨ve T cells (Figure 4d). Moreover, activated CD4+ T cells dramatically increase expression of
UHRF1, which is required for DNMT1 recruitment and activity (Nishiyama et al., 2016). The expres-
sion of the polycomb repressive complex 2 (PRC2), which is responsible for histone 3 lysine 27 meth-
ylation (H3K27), is also highly increased upon T cell activation and in differentiated effector T cells
compared with naı¨ve T cells (Figure 4e,f) as is expression of other key histone methyltransferases,
responsible for histone methylations including H3K4, K9 and K36 and H4K20 methylation
(Bochynska et al., 2018; Mozzetta et al., 2015; Wagner and Carpenter, 2012) (Figure 4g).
One striking observation in the current study was that even short periods of methionine depriva-
tion cause a loss of RNA and histone methylations. A key question then, is whether the dependence
of these cells on extracellular methionine for histone and RNA methylation reflects that methionine
is needed to sustain expression of the methionine cycle enzymes and/or RNA and histone methyl-
transferases. To address this question, we used mass spectrometry to assess the impact of acute
methionine deprivation on the proteome of effector Th1 CD4+ T cells. In these experiments, Th1
CD4+ T cells were switched into media containing 1mM or 100mM methionine for 5 hr prior to proc-
essing for single-shot proteomics from which we identified 4’400 proteins. The data shows that the
protein expression profile did not significantly vary upon acute methionine deprivation, with a very
high correlation coefficient between the two conditions of 0.98 (Figure 5a). Proteins that showed
significant changes in expression (increased or decreased) are listed in Figure 5b.
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With regard to the methionine cycle specifically, these experiments found that acute short term
methionine deprivation of Th1 cells had no impact on expression of key enzymes including; MAT2A,
AHCY, SRM/SMS,MTAP and mtnA (Figure 5c–g). The expression of RNA, DNA and histone methyl
transferases was also not changed by short-term methionine restriction (Figure 5h–j). The need for T
cells to sustain supply of methionine to maintain the methionine cycle is thus explained by the need
for methionine to produce methyl donors.
The impact of methionine restriction on c-myc expression and mTORC1
activity
How much does methionine deprivation impact on other metabolic programs in T cells? In this con-
text, the serine/threonine kinase mTORC1 and the transcription factor c-myc can be described as
hubs of metabolic regulation in T cells. Appropriate mTORC1 activity and c-myc expression are criti-
cal for correct effector T cell responses (Xu et al., 2012; Zeng and Chi, 2017; Wang et al., 2011).
In both T cells and NK cells, expression of c-myc protein is highly sensitive to amino acid availability
and expression of amino acid transporters (Sinclair et al., 2013; Loftus et al., 2018). To explore
whether c-myc expression was dependent upon extracellular methionine availability, we used a
mouse model where a fusion protein of GFP-Myc is expressed under the control of the endogenous
Myc promoter (GFP-MycKI) (Huang et al., 2008; Preston et al., 2015). GFP-MycKI CD4+ T cells
increase expression of the activation marker CD69 in response to TCR/CD28 stimulation in both the
presence (100mM) and absence of methionine. The data show that the induction of GFP-Myc expres-
sion in response to TCR/CD28 activation is blunted in the absence of methionine (Figure 6a,b).
It has also recently been demonstrated that methionine availability regulates mTORC1 activity
through metabolite SAM binding to SAMTOR; SAM- SAMTOR then associates with and inhibits
GATOR1, resulting in lysosomal recruitment and activation of mTORC1 (Gu et al., 2017;
Valvezan and Manning, 2019). To investigate whether mTORC1 activity in T cells is sensitive to
extracellular methionine availability, effector CD4+ Th1 cells were switched to methionine free condi-
tions and the impact of this on mTORC1 activity in Th1 cells was assessed. The data show mTORC1
activity in T cells was partially sensitive to methionine deprivation, though the impact of methionine
loss was not equivalent to total amino acid deprivation or rapamycin treatment (Figure 6c,d). Treat-
ment with SAM (50mM) modestly restores mTORC1 activity in the absence of methionine (Figure 6e,
f). These data show that methionine availability and the production of SAM can feed into control of
mTORC1 activity. The impact of methione deprivation on c-myc expression and mTORC1 activity
highlights the diversity of cellular responses in T cells that are able to sense the external methionine
environment.
Control of the methionine cycle in T cells via controlled expression of
methionine transport
The proteomic data reveal that increased flux through the methionine cycle and increases in RNA
methylation are not explained by changes in the abundance of the key enzymes of the methionine
cycle or the RNA methyl transferases. However, the sustained availability of extracellular methionine
is critical which raises the possibility that the rate limiting step for methionine metabolism in acti-
vated T cells is the rate of methionine transport. To investigate the methionine transport capacity of
naı¨ve versus effector T cell populations, we compared radiolabeled methionine uptake in naı¨ve and
activated T lymphocytes. Naı¨ve CD4+ T cells show very little/near undetectable uptake of 3H-labeled
methionine (Figure 7a) whereas methionine transport was readily detected in CD4+ T cells activated
with CD3/CD28 crosslinking antibodies and in effector Th1 cells (Figure 7a). Figure 7b show that
Figure 4 continued
(PRC2) uses SAM to methylate lysine residues for example K27 on histone tails. Concentration of the PRC2 components calculated from proteomics
data from naı¨ve CD4+ T cells (naı¨ve), 24 hr TCR- stimulated CD4+ T cells (TCR) and in vitro generated Th1 cells (Th1). (g) Flow cytometry plots showing
EZH2 staining in naı¨ve CD4+ T cells, CD4+ T cells stimulated through the TCR (aCD3/aCD28, IL2/12) for 18 hr and in vitro generated Th1 cells. MFI are
shown on the graph. (h) Concentrations of histone methyltransferases calculated from proteomics data of naı¨ve CD4+ T cells (naı¨ve), 24 hr TCR-
stimulated CD4+ T cells (TCR) and in vitro generated Th1 cells (Th1). Histone methyl modifications are indicated. (Error bars are mean ± s.d. Data are
from three biological replicates.).
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Figure 5. Acute methionine restriction on methionine cycle proteome Quantitative ‘single-shot’ proteomics was performed on in vitro generated IL2
maintained Th1 cells cultured for 5 hr in 100 mM or 1 mM methionine. (a) The graph shows the protein copy numbers in Th1 cultured with 1 mM
methionine plotted against those in 100 mM methionine. Pearson correlation is indicated. (b) Proteins that were significantly differentially expressed
(P = <0.05, with a 1.5 fold cut-off) are listed by gene name. They are ranked as most decreased by acute methionine deprivation to those that are
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the high levels of methionine transport in Th1 cells is dependent on sustained signalling via the IL2
receptor. Hence, either the removal of IL2, or the exposure of cells to limiting IL2 concentrations,
results in a decrease of 3H-methionine uptake. Together, these data demonstrate that naı¨ve CD4+ T
lymphocytes greatly increase methionine uptake in response to antigenic stimulation. These changes
in methionine transport could reflect changes in either the expression or activity of T cell methionine
transporters.
Mammalian methionine transporters include the System ASC (alanine-serine-cysteine preferring)
transporter SLC1A5; the System L transporters SLC7A5 and SLC7A8; the System y + L transporters
SLC7A6 and SLC7A7; and the System A transporters SLC38A1 and SLC38A2 (Utsunomiya-
Tate et al., 1996; Baird et al., 2009; Bro¨er and Palacı´n, 2011; Kanai et al., 1998; Nii et al., 2001;
Napolitano et al., 2015). Interrogation of the naı¨ve, TCR and effector T cell proteomic data identi-
fied several candidate methionine transporters in TCR stimulated CD4+ T cells and effector Th1s;
notably SLC1A5, SLC7A5, SLC7A6 and SLC38A2 (SNAT2) (Figure 7c). The candidate methionine
Figure 5 continued
increased. (c-g) The graphs show mean copy numbers (estimated using the proteomic ruler protocol) of (c) MAT2A, (d) AHCY, (e) SMS/SRM, (f) MTAP
and (g) mtnA. (h-j) The graphs show mean copy numbers of (h) RNA cap methyltransferases RNMT and CMTR1; (i) DNA methyltransferase complex
components UHRF1, DNMT1 and DNMt3a and (j) histone methyltransferases SUV39H1, SETD3 and EZH2. (Error bars are mean ± s.d. Data are from
three biological replicates.).
DOI: https://doi.org/10.7554/eLife.44210.008
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transporters that were detected in activated T cells have different expression levels: the most abun-
dant candidates were SLC7A5 and SLC1A5 (ASCT2). SLC7A6, and SLC38A2 (SNAT2) are both
expressed at far lower levels than SLC7A5. The proteomic data moreover reveal the basis for the
failure of naı¨ve T cells to transport methionine: they have a very low copy number of any candidate
methionine transporter (Figure 7c). Hence in contrast to methionine cycle enzymes which are abun-
dantly expressed in naı¨ve and effector CD4+ T cells, expression of methionine transporters is
restricted to TCR activated and effector T cells.
One way to address which methionine transporter dominates in activated T cells is to use selec-
tive pharmacological approaches that would distinguish the different candidates. For example, 2-
aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH) is a competitive blocker for System L transport-
ers (Verrey et al., 2004); MeAIB competitively blocks SLC38A2 (Mackenzie and Erickson, 2004).
Alanine has a high affinity for SLC1A5 (Kanai and Hediger, 2004); lysine is transported preferentially
by SLC7A6. Accordingly, alanine and lysine competition of methionine transport can be used as evi-
dence for involvement of SLC1A5 or SLC7A6 respectively (Verrey et al., 2004). Furthermore,
SLC1A5, SLC38A2 and SLC7A6 are all dependent on sodium to mediate methionine transport
(Kanai and Hediger, 2004; Mackenzie and Erickson, 2004; Verrey et al., 2004). Accordingly we
assessed the biochemical properties of the methionine transporters in activated T cells. The data
show that 3H-methionine uptake in CD4+ effector Th1 cells is blocked by BCH. The data also show
that competition by either Alanine, Lysine or MeAIB which would block System A mediated uptake
has little impact on methionine transport in activated CD4+ T cells (Figure 7d). Furthermore, 3H-
methionine uptake in effector CD4+ T cells is sodium independent (Figure 7e). This contrasts with
glutamine uptake in the same effector cells, which is not affected by BCH and is sodium dependent
(Figure 7e,f). Collectively these data establish that methionine transport in activated T cells is via
System L transporters. Further evidence for this conclusion is shown in Figure 6g: the cellular uptake
of the System L substrate 3H-phenylalanine is competitively inhibited by methionine (Figure 7h); 3H-
methionine incorporation into protein in activated T cells is blocked by the System L transport inhibi-
tor BCH (Figure 7h); TCR induced production of methylated RNA is prevented in the presence of
BCH (Figure 7i); BCH treatment reduces SAH levels in TCR activated CD4+ T cells (Figure 7j); m6A
mRNA methylation is reduced in the presence of BCH (Figure 7k). Collectively these data show that
methionine delivery mediated via System L amino acid transporters is the rate limiting step for the
methionine cycle in T cells and rate limiting for protein synthesis and RNA methylation. The only Sys-
tem L candidate identified in the proteomics was SLC7A5 and this was also very abundant
(Figure 7c). To test the involvement of SLC7A5 directly we examined the methionine transport
capacity of T cells lacking SLC7A5 expression. Figure 7l shows that SLC7A5 null CD4+ T cells do not
increase methionine uptake in response to activation with CD3/CD28 antibodies. SLC7A5 null CD4+
T cells T cells also show a striking decrease in their ability to increase levels of the methionine metab-
olite SAH in response to TCR/CD28 stimulation (Figure 7m). This is consistent with SLC7A5 expres-
sion being required for the increased flux of methionine through the methionine cycle in response to
TCR activation and differentiation.
Figure 7 continued
cells in the presence or absence of BCH, ALA, LYS, MeAIB or MET (all 5 mM). (e) Uptake of 3H-methionine (left panel) or 14C glutamine (right panel) in
IL2 maintained Th1 cells in presence or absence of sodium in the uptake buffer. (f) 14C-glutamine uptake in IL2 maintained Th1 cells in the presence or
absence of GLN, ALA and BCH (all 5 mM). (g) 3H-phenylalanine uptake in IL2 maintained Th1 cells in the presence or absence of BCH, ALA, LYS, LEU or
MET (all 5 mM). (h–i) 3H radioactivity of TCA precipitated protein (h) or RNA (i) from CD4+ T cells stimulated through the TCR (CD3/CD28) for 6 hr in the
presence of 3H-methionine ± the System L inhibitor BCH. (j) SAH levels as determined by ELISA in CD4+ T cells stimulated through the TCR (CD3/
CD28)±the System L inhibitor BCH for 18 hr. (k) Percentage of RNA with m6A modification, as determined by ELISA, in Th1 cells cultured in 20 mM
MET ±BCH for 5 hr. (l) Uptake of 3H-methionine in TCR stimulated (CD3/CD28, 18 hr) CD4+ T cells from Slc7a5fl/fl or Cd4-Cre+::Slc7a5fl/fl mice,
compared to unstimulated CD4+ T cells maintained in IL7,±System L transporter inhibitor BCH (5 mM). (m) SAH levels in CD4+ T cells from Slc7a5fl/fl or
Cd4-Cre+::Slc7a5fl/fl mice stimulated through the TCR (CD3/CD28) for 18 hr, compared to naive cells. ((a,b- d, f, g, l, m) ANOVA, (e,h–k) t-test; P=
*<0.05, **<0.01, ***<0.001, ****<0.0001. Uptakes performed in triplicate. Error bars are s.d. from minimum three biological replicates. Points indicate
individual biological replicates.).
DOI: https://doi.org/10.7554/eLife.44210.010
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Discussion
The present study explores how T cells control a fundamental metabolic pathway and shows that
antigen receptor triggering of T cells initiates a cycle of methionine metabolism that generates the
methyl donors required for RNA and histone methylation. We establish that a critical, rate limiting
step to fuel protein synthesis and the methionine cycle in T cells is antigen receptor and cytokine
regulation of methionine transport across the cell membrane. Naı¨ve T lymphocytes express high lev-
els of all the key methionine cycle enzymes but cannot transport sufficient methionine to provide the
substrates for these enzymes or to fuel protein synthesis. The methionine cycle and protein synthesis
are thus only initiated in T cells when antigen receptor engagement signals the expression of methi-
onine transporters that support high rates of methionine transport. This provides some new under-
standing regarding mechanisms that ensure the immunological specificity of effector T cell
differentiation. Only T cells that respond to antigen to upregulate methionine transport will be able
to fuel protein synthesis and supply the methyl donors that permit the dynamic nucleotide methyla-
tions and epigenetic reprogramming that drives T cell differentiation.
Activated T cells express multiple candidate mammalian methionine transporters, therefore we
have used a combination of pharmacological and genetic strategies and pinpoint that the sodium
independent System L amino acid transporter, SLC7A5 is the dominant methionine transporter in
activated T cells. Previous studies have shown that SLC7A5 is important for T cell differentiation in
vitro and in vivo (Sinclair et al., 2013) and proposed that this reflected the role of SLC7A5 as the
key leucine transporter in activated T cells and its subsequent role in regulating the activity of the
leucine sensing kinase mammalian target of rapamycin complex 1 (mTORC1). The present data pro-
vide additional novel information as to why SLC7A5 is critically important for T cells; it is required to
transport methionine. The present data further highlight that the importance of SLC7A5 for T cell
biology reflects that it is a common transporter for multiple essential amino acids.
The dependence of T cell activation, differentiation and proliferation on extracellular methionine
was striking and indicates that T cells cannot rely on methionine salvage pathways or autophagy of
intracellular cargo to meet their demands for methionine. One reason methionine supply is so impor-
tant for immune T cells is to fuel de novo protein synthesis. For example, we show that the expres-
sion of c-myc, a critical transcription factor for T cells, is controlled by external methionine
availability and this is a simple reflection of the fact that proteins with a short half life like c-myc will
be dependent on sustained availability of amino acids. In this latter context, it has been shown that
in vivo activated CD8+ T cells exhibit dynamic control of translation as they differentiate from naı¨ve
(low translation rates) into effector (high translation rates) and memory (low translation rates) cells
(Araki et al., 2017). The present data highlight that the most critical rate limiting step for mRNA
translation is the rate of methionine transport via the System L transporter SLC7A5 because it is this
transporter that determines intracellular methionine bioavailability. We have previously shown that
SLC7A5 expression is restricted to TCR activated effector cells and low in naı¨ve and memory T cells
(Sinclair et al., 2013; Preston et al., 2015). The dynamic changes in mRNA translation observed by
Araki et al. (2017) could thus reflect changes in the methionine transport capacity of naı¨ve versus
effector versus memory T cells.
One other insight from present data was how much T cells depend on an external methionine
supply and the controlled expression of methionine transporters to sustain the production of
S-adenosylmethionine (SAM), the methyl donor for DNA, RNA and protein methyltransferases.
Methionine availability and SAM production also modulate mTORC1 activity in T cells analogous to
the recently described methionine/SAM sensing pathways that regulate mTORC1 in HEK 293 T cells
(Gu et al., 2017). The supply of methyl donors for protein and nucleotide methylations is critical for
many cellular processes. For example, mRNA cap methylation controls mRNA binding and transla-
tion (Gonatopoulos-Pournatzis and Cowling, 2014); the methylation of adenosine, ‘m6A’, in mRNA
controls mRNA stability and is important for T cell homeostasis (Li et al., 2017). The data herein
give new insights namely that engagement of the TCR induces RNA methylation and it is the ability
of TCR triggering to control methionine transport to fuel the methionine cycle that allows the TCR
to control RNA methylation. In this context the TCR does not control expression of the RNA methyl-
transferases; these are already present in naive T cells. The generation of methyl donors by the
methionine cycle is also necessary for DNA methylations which are known to be critical for the tran-
scriptional reprogramming that controls T cell differentiation with both increased and repressed
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transcription of multiple genes, coordinated by changes in DNA methylations (Crompton et al.,
2016; Youngblood et al., 2017; Thomas et al., 2012; Hashimoto et al., 2013; Makar and Wilson,
2004; Ladle et al., 2016). Regulated changes in histone methylation are also critical for T cell
(Henning et al., 2018). Our quantitative proteomics analysis revealed that expression of histone
methylation complexes is low in naı¨ve T cells and increased upon T cell activation. The ability of
immune activated T cells to control histone methylations requires the co-ordination of the expression
of methionine transporters to supply the methionine cycle to make methyl donors as well as to sup-
ply methioinine for ‘building’ the expression of the key methyltransferase complexes. This is in con-
trast to the control of RNA methylation where methyltransferases responsible for RNA modifications
are present in naı¨ve T cells and poised awaiting substrate availability. The present work highlights
that a full understanding of epigenetic control of cell phenotypes and the importance of RNA meth-
ylations requires knowledge of the rate limiting processes that control the methionine cycle under
physiological conditions. Hence identification of methionine transporters and understanding the
molecular details of how methionine transporter expression is regulated is important to understand
how cells control the supply of methyl donors to support key biological processes. In this respect the
importance of methionine bio-availability to other cell lineages is now recognized eg for liver cells
and embryonic stem cells (Tang et al., 2017; Shiraki et al., 2014; Mentch et al., 2015). However,
these studies do not explore or discuss the possibility that methionine availability to cells is deter-
mined by regulated expression of methionine transporters. There is only a limited understanding of
the identity of the relevant methionine transporters in different cell types and very little understand-
ing of the signals that control expression of methionine transporters in different tissues.
Finally, the importance of regulated changes in methionine transport for T cell activation predict
that changes in dietary methionine, as seen by Mentch et al. (2015), could impact on T cell function.
Extracellular methionine availability in plasma is thus dependent upon dietary intake and dietary
methionine restriction has been shown to alter histone methylation in the liver (Mentch and Loca-
sale, 2016; Mentch et al., 2015). Whether a T cell would encounter limiting methionine concentra-
tions is unknown, but it is a possibility. In particular it is possible that T cells may have limited access
to methionine if they are positioned in tissues where other cells compete for nutrients. For example
in a tumour microenvironment. The present data indicate that any study of how dietary methionine
impacts any cell will need to consider the impact of restricting methionine on a range of intracellular
signaling and metabolic pathways, RNA modifications and mRNA stability and not only consider the
availability of methionine for protein synthesis.
Materials and methods
Key resources table
Reagent type (species) or
resource Designation
Source or
reference Identifiers
Additional
information
Genetic reagent (M.
musculus)
JAX C57BL/6J,
WT
JAX C57BL/6J Mice, Charles
River
UK
strain
code 632
Genetic reagent (M.
musculus)
Cd4Cre Slc7a5fl/fl Sinclair et al., 2013
Genetic reagent (M.
musculus)
GFP-MycKI Huang et al., 2008;
Preston et al., 2015
In these mice, a fusion protein of Myc
and enhanced green
fluorescent protein
(GFP-Myc) is expressed
from the endogenous
Myc locus (GFP-MycKI)
Genetic reagent (M.
musculus)
OT2 Barnden et al., 1998 maintained in house
on a CD45.1 (LY5.1)
background
Antibody Anti-CD3 (armenian
hamster,
monoclonal)
ThermoFisher Cat #
14-0031-82, RRID:
AB_467049
T cell activation: 1 mg/ml; Th1
differentiation: 2 mg/ml
Continued on next page
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Continued
Reagent type (species) or
resource Designation
Source or
reference Identifiers
Additional
information
Antibody Anti-CD28 (syrian
hamster,
monoclonal)
ThermoFisher Cat #
16-0281-82, RRID:
AB_468921
T cell activation: 2 mg/ml; Th1
differentiation: 3 mg/ml
Antibody Anti-CD4
(rat, monoclonal)
Biolegend Cat #
100530, RRID:
AB_389325
cell surface
staining 1:200
Antibody Anti-TCRb (armenian
hamster,
monoclonal)
Biolegend Cat #
109220, RRID:
AB_893624
cell surface
staining 1:200
Antibody Anti-CD62L (rat, monoclonal) Biolegend Cat #
104412, RRID:
AB_313099
cell surface
staining 1:200
Antibody Anti-TCR V
alpha 2 (rat,
monoclonal)
Biolegend Cat #
127808, RRID:
AB_1134183
cell surface
staining 1:200
Antibody Anti-CD44
(rat, monoclonal)
Biolegend Cat #
103030, RRID:
AB_830787
cell surface
staining 1:200
Antibody Anti-CD45.1 (mouse,
monoclonal)
Biolegend Cat #
110714, RRID:
AB_313503
cell surface
staining 1:200
Antibody Anti-CD45.2 (mouse,
monoclonal)
Biolegend Cat #
109816, RRID:
AB_492868
cell surface
staining 1:200
Antibody Anti-CD69 (armenian
hamster,
monoclonal)
Biolegend Cat #
104522, RRID:
AB_2260065
cell surface
staining 1:200
Antibody Anti-INFg
(rat, monoclonal)
Biolegend Cat #
505810, RRID:
AB_315404
intracellular
cytokine staining
1:50
Antibody Anti-phospho-S6 (rabbit,
monoclonal)
Cell Signaling
Technologies
Cat #
2211, RRID:
AB_331679
intracellular
staining 1:50
Antibody Anti-Histone H3 (rabbit,
monoclonal)
Cell Signaling
Technologies
Cat # 82241S intracellular
staining 1:50
Antibody Anti-Histone H3K4me3
(rabbit,
monoclonal)
Cell Signaling
Technologies
Cat # 12064 intracellular
staining 1:50
Antibody Anti-H3K27me3
(rabbit,
monoclonal)
Cell Signaling
Technologies
Cat # 12158 intracellular
staining 1:50
Antibody Anti-rabbit A647 Cell Signaling
Technologies
Cat #
4414, RRID:
AB_10693544
intracellular
staining 1:500
Antibody Anti-mouse CD16/CD32 Fc
Block, (rat,
monoclonal)
BD
Biosciences
Cat #
553141, RRID:
AB_394656
Fc block 1:70
Peptide,
recombinant
protein
IL2 Novartis, UK Proleukin Th1 differentiation:
20 ng/ml
Peptide,
recombinant
protein
IL12 RnD Systems,
UK
Cat # 419 ML Th1 differentiation:
10 ng/ml
Peptide,
recombinant
protein
NP-OVA BioSearch technolgies,
UK
Cat # N-5051 Immunisation
100 mg per
mouse
Continued on next page
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Continued
Reagent type (species) or
resource Designation
Source or
reference Identifiers
Additional
information
Commercial
assay or kit
EasySep CD8
positive
isolation kit
STEMCELL Technologies,
UK
Cat # 19853
Commercial
assay or kit
SAH Elisa Axis-Shield Cat # FHCY100
Commercial
assay or kit
m6A methylation Epigentek Cat # P-9005
Commercial
assay or kit
m5C methylation Epigentek Cat # P-9009
Commercial
assay or kit
Rneasy
minikit
Qiagen Cat # 74104
Chemical
compound,
drug
Imject Alum Pierce, UK Cat # 77161 Immunisation
adjuvant
Chemical
compound,
drug
OPP Jena Bioscience Cat # NU-931 20 mM,
10 min incubation
Chemical
compound,
drug
Click EdU Carbosynth Cat # NE08701 10 mM,
45 min incubation
Chemical
compound,
drug
Click EU ThermoFisher Cat # E10345 500 mM,
30 min incubation
Chemical
compound,
drug
Alexa 647
azide
ThermoFisher Cat # A10277 5 mM, in Click
reaction buffer
Chemical
compound,
drug
Actinomycin D Sigma Cat # A1410 5 mg/ml, 45 min
Chemical
compound,
drug
Cyclohexamide Sigma Cat # C7698 100 mg/ml, 30 min
Chemical
compound,
drug
Rapamycin ThermoFisher Cat # PHZ1235 20 nM
Chemical
compound,
drug
[3H] L-
methionine
PerkinElmer Cat # NET061  001MC 1 mci/ml uptake buffer
Chemical
compound,
drug
[3H] L-
phenylalanine
PerkinElmer Cat #
NET1122001MC
0.5 mci/ml uptake
buffer
Chemical
compound,
drug
[14C] L-
glutamine
PerkinElmer Cat #
NEC451050UC
0.1 mci/ml
uptake
buffer
Chemical
compound,
drug
silicone oil Sigma Cat # 175633 layering buffer
for uptake assay
Chemical
compound,
drug
dibutyl pthalate Sigma Cat # 524980 layering buffer
for uptake assay
Chemical
compound,
drug
Optiphase HiSafe 3 PerkinElmer Cat # 1200.437 scintillant
Software,
algorithm
FlowJo software Treestar versions 9 and 10
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Mice and cells
C57BL/6 (wild-type, WT), Cd4-Cre::Slc7a5fl/fl, GFP-MycKI and OT2 TCR transgenic mice were bred
and maintained in the WTB/RUTG, University of Dundee in compliance with UK Home Office Animals
(Scientific Procedures) Act 1986 guidelines.
To activate primary T cells, lymph nodes were removed and disaggregated. Cells were cultured
in RPMI 1640 containing L-glutamine (Invitrogen, ThermoFisher Scientific, UK), 10% FBS (Gibco,
ThermoFisher Scientific, UK), 50 mM b-mercaptoethanol (b-ME, Sigma-Aldrich, UK) and penicillin/
streptomycin (Gibco). Cells were stimulated with 1 mg/ml of the CD3 monoclonal antibody (2C11)
and 2 mg/ml anti-CD28 (37.51; ebiosciences, ThermoFisher Scientific, UK) in the presence of cyto-
kines IL12 (10 ng/ml; RnD Systems, UK) and 20 ng/ml IL2 (20 ng/ml; Proleukin, Novartis, UK). To gen-
erate Th1s, murine CD8+ T cells were depleted from lymph node preparations using CD8 depletion
kit (EasySep, STEMCELL Technologies, UK). The resulting mix of CD4+ T cells and APC were cul-
tured at 3  105 cells/ml for 5 days in the presence of anti-CD3 (2 mg/ml) and anti-CD28 (3 mg/ml)
and cytokines IL12 (10 ng/ml) and 20 ng/ml IL2 (20 ng/ml). For proteomics samples, naı¨ve CD4+ T
cells were isolated from lymph node and sorted gated on CD4+, CD62Lhigh and CD44low. Live TCR
activated CD4+ cells and Th1 cells were sorted for CD4+ expression and DAP1 exclusion. Cells were
then cultured in 100 mM or 1 mM methionine for a further 5 hr before processing for single-shot pro-
teomics analysis.
Where indicated, methionine free RPMI (ThermoFisher) was supplemented with 10% dialysed FBS
(ThermoFisher) and reconstituted with L-methionine (Sigma).
Cells were incubated at 37 ˚C with 5% CO2 throughout.
Adoptive transfers and ova immunisation
For in vivo activation and proliferation, OT2 (CD45.1) lymph node cells were injected into C57/Bl6
(CD45.2) hosts. After 24 hr, mice were immunised i.p. with 4-Hydroxy-3-nitrophenylacetyl hapten
conjugated to ovalbumin (NP-OVA; 100 mg; BioSearch technologies, UK) adsorbed to alum (Pierce,
UK). Spleens were harvested and transferred cells were identified and analysed at D3 after
activation.
Flow cytometry
For cell surface staining, antibodies conjugated to FITC, PE, APC, AlexaFluor 647, APC-efluor780,
AlexaFluor 700, PerCPCy5.5, Brilliant Violet 421 and 605 were obtained from either BD Biosciences,
eBioscience or Biolegend. Fc receptors were blocked using Fc Block (BD Biosciences). Antibody
clones used were: CD4 (RM4-5), TCRb (H57-597), Va2 (B20.1), CD62L (MEL-14), CD44 (IM7), CD45.1
(A20), CD45.2 (104), CD69 (H1.2F3). Cells were fixed using 1% paraformaldehyde. Standard intracel-
lular cytokine staining protocols were followed for INFg (clone XMG1.2; Biolegend) staining.
For intracellular histone methylation staining or phospho-S6 staining, cells were permeabilised
post fixation by incubation with 90% (v/v) methanol at  20˚C for at least 30 min. Following permea-
bilisation, cells were washed twice and incubated with antibody against Tri-methyl-Histone H3 (Lys
27; clone C36B11), Tri-methyl-Histone H3 (Lys 4; clone C42D8), Histone H3 (clone D1H2 XP) or phos-
pho-S6 Ser235/236 (# 2211) with anti-rabbit Alexa 647 (# 4414) secondary (Cell Signaling Technol-
ogy). Cells were then washed and resupended in 0.5% FBS (v/v) in PBS for acquisition.
For flow cytometry assays for protein, RNA and DNA synthesis; cells were treated with either 20
mM O-propargyl-puromycin (OPP, Jena Bioscience) for 10 min, Click-iT EdU (10 mM; Thermo Fisher)
for 45 mins or Click-iT EU (2 mM; Thermo Fisher) for 30 mins. The incorporation of the analogues
into newly synthesized protein, RNA and DNA was measured by labelling with Alexa 647-azide (Invi-
trogen) using a standard Click-IT chemistry reaction (Thermo Fisher). As negative controls, cyclohex-
amide (100 mg/ml; Sigma; 30mins) and Actinomycin D (5 mg/ml; Sigma; 45 min) were added to stop
protein and RNA synthesis, respectively.
Data were acquired on a LSR Fortessa II with DIVA software or a FACSVerse flow cytometer with
FACSuite software (BD Biosciences) and analyzed using FlowJo software (TreeStar, version 9 and
10). Gating strategies are shown in Supplemental data.
Sinclair et al. eLife 2019;8:e44210. DOI: https://doi.org/10.7554/eLife.44210 20 of 29
Research article Immunology and Inflammation
SAH measurements
S-adenosyl-homocysteine (SAH) levels were measured using a competitive ELISA (Axis Homocysteine
EIA, FHCY 100, Axis-Shield) as recommended, omitting the primary enzymatic conversion of homo-
cysteine to SAH step.
Radiolabelled nutrient uptake
Briefly, nutrient uptake was carried out using 1  106 cells resuspended in 0.4 ml uptake medium.
Each uptake for a biological replicate is performed in triplicate. Methionine uptake was carried out
in HBSS (ThermoFisher Scientific) containing [3H] L-methionine (1 mci/ml) and a final extracellular
L-methionine concentration of 0.5 mm. Similarly, phenylalanine uptake was performed using [3H]
L-phenylalanine (0.5 mci/ml) and a final extracellular L-leucine concentration of 0.5 mm. 2 min uptake
assays were carried out layered over 0.5 ml of 1:1 silicone oil (Dow Corning 550 (BDH silicone prod-
ucts; specific density, 1.07 g/ml):dibutyl phthalate (Fluka). Where indicated, [14C] L-glutamine (0.1
mci/ml) was added to assay glutamine uptake simultaneously. Cells were pelleted below the oil, the
aqueous supernatant solution, followed by the silicon oil/dibutyl phthalate mixture was aspirated,
and the cell pellet underneath resuspended in 200 ml NaOH (1M) and b-radioactivity measured by
liquid scintillation counting in a Beckman LS 6500 Multi-Purpose Scintillation Counter (Beckman
Coulter). Where indicated, 5 mM BCH, L-Alanine, L-Lysine, L-Leucine, L-Methionine or MeAIB were
used respectively to quench radiolabeled ligand uptake. The sodium free buffer was TMACl as
described in Baird et al. (2009). Data is expressed as molecules radiotracer per cell per minute. [3H]
L-methionine, [3H] L-phenylalanine and [14C] L-glutamine were obtained from Perkin Elmer. All other
chemicals were obtained from Sigma.
3H- methionine incorporation
IL2/12 maintained effector Th1 cells were cultured with 3H-methionine for 6 hr. Protein from 5  106
cells was precipitated with 0.5 ml 10% trichloroacetic acid (TCA), for 15mins at room temperature.
The protein pellet was washed (x3) with cold acetone, and acetone was allowed to evaporate. RNA
was isolated from 5  106 cells with RNeasy minikit (Qiagen), and quantified by NanoDrop (Thermo-
Fisher). Samples were resuspended in scintillation fluid (Optiphase HiSafe 3, PerkinElmer) and 3H
radioactivity in TCA precipitated protein, or RNA was measured by liquid scintillation counting in a
Beckman LS 6500 Multi-Purpose Scintillation Counter (Beckman Coulter).
m6A and m5C RNA methylation m6A and m5C RNA methylation was quantified using the fluoro-
metric EpiQuik m6A or 5-mC RNA Methylation quantification Kit (Epigentek) respectively, following
RNA isolation from 5  106 cells using RNAEasy minikit (Qiagen).
Metabolomics:
Metabolite extraction-
Metabolite extraction was performed as described in previous study (Liu et al., 2015). The superna-
tant was transferred to a new Eppendorf tube and dried in vacuum concentrator at room tempera-
ture. The dry pellets were reconstituted into 30 ml sample solvent (water:methanol:acetonitrile, 2:1:1,
v/v) and 3 ml was further analyzed by liquid chromatography-mass spectrometry (LC-MS).
LC-MS method-
Ultimate 3000 UHPLC (Dionex) is coupled to Q Exactive-Mass spectrometer (QE-MS, Thermo Scien-
tific) for metabolite profiling. A hydrophilic interaction chromatography method (HILIC) employing
an Xbridge amide column (100  2.1 mm i.d., 3.5 mm; Waters) is used for polar metabolite separa-
tion. Detailed LC method was described previously (Liu et al., 2014b) except that mobile phase A
was replaced with water containing 5 mM ammonium acetate (pH 6.8). The QE-MS is equipped with
a HESI probe with related parameters set as below: heater temperature, 120˚C; sheath gas, 30; aux-
iliary gas, 10; sweep gas, 3; spray voltage, 3.0 kV for the positive mode and 2.5 kV for the negative
mode; capillary temperature, 320˚C; S-lens, 55; scan range (m/z): 70 to 900; resolution: 70000; auto-
mated gain control (AGC), 3  106 ions. Customized mass calibration was performed before data
acquisition.
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Metabolomics data analysis
LC-MS peak extraction and integration were performed using commercial available software Sieve
2.2 (Thermo Scientific). The peak area was used to represent the relative abundance of each metab-
olite in different samples. The missing values were handled as described in previous study (Liu et al.,
2014b).
Proteomics
Naı¨ve CD4+ and effector Th1 (TMT labelled)
Sample preparation and TMT labelling
Cell pellets were lysed in 400 mL lysis buffer (4% SDS, 50 mM TEAB pH 8.5, 10 mM TCEP). Lysates
were boiled and sonicated with a BioRuptor (30 cycles: 30 s on, 30 s off) before alkylation with
iodoacetamide for 1 hr at room temperature in the dark. The lysates were subjected to the SP3 pro-
cedure for protein clean-up (Hughes et al., 2014) before elution into digest buffer (0.1% SDS, 50
mM TEAB pH 8.5, 1 mM CaCl2) and digested with LysC and Trypsin, each at a 1:50 (enzyme:protein)
ratio. TMT labelling and peptide clean-up were performed according to the SP3 protocol. Samples
were eluted into 2% DMSO in water, combined and dried in vacuo.
Basic reverse-phase fractionation
The TMT samples were fractionated using off-line high pH reverse phase chromatography: samples
were loaded onto a 4.6  250 mm Xbridge BEH130 C18 column with 3.5 mm particles (Waters).
Using a Dionex BioRS system, the samples were separated using a 25 min multistep gradient of sol-
vents A (10 mM formate at pH 9 in 2% acetonitrile) and B (10 mM ammonium formate pH 9 in 80%
acetonitrile), at a flow rate of 1 mL/min. Peptides were separated into 48 fractions which were con-
solidated into 24 fractions. The fractions were subsequently dried and the peptides redissolved in
5% formic acid and analysed by LC-MS.
Liquid chromatography electrospray tandem mass spectrometry analysis
(LC-ES-MS/MS)
1 mg per fraction was analysed using an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scien-
tific) equipped with a Dionex ultra high-pressure liquid chromatography system (nano RSLC). RP-LC
was performed using a Dionex RSLC nano HPLC (Thermo Scientific). Peptides were injected onto a
75 mm  2 cm PepMap-C18 pre-column and resolved on a 75 mm  50 cm RP- C18 EASY-Spray tem-
perature controlled integrated column-emitter (ThermoFisher) using a four hour multistep gradient
from 5% B to 35% B with a constant flow of 200 nL min 1. The mobile phases were: 2% ACN incor-
porating 0.1% FA (Solvent A) and 80% ACN incorporating 0.1% FA (Solvent B). The spray was initi-
ated by applying 2.5 kV to the EASY-Spray emitter and the data were acquired under the control of
Xcalibur software in a data dependent mode using top speed and 4 s duration per cycle, the survey
scan is acquired in the Orbitrap covering the m/z range from 400 to 1400 Th with a mass resolution
of 120,000 and an automatic gain control (AGC) target of 2.0 e5 ions. The most intense ions were
selected for fragmentation using CID in the ion trap with 30% CID collision energy and an isolation
window of 1.6 Th. The AGC target was set to 1.0 e4 with a maximum injection time of 70 ms and a
dynamic exclusion of 80 s. During the MS3 analysis for more accurate TMT quantifications, 10 frag-
ment ions were co-isolated using synchronous precursor selection using a window of 2 Th and fur-
ther fragmented using HCD collision energy of 55%. The fragments were then analysed in the
Orbitrap with a resolution of 60,000. The AGC target was set to 1.0 e5 and the maximum injection
time was set to 300 ms.
Database searching and reporter ion quantification
The data were processed, searched and quantified with the MaxQuant software package, version
1.5.8.3, Proteins and peptides were identified using the UniProt mouse reference proteome data-
base (SwissProt and Trembl) and the contaminants database integrated in MaxQuant using the
Andromeda search engine (Cox and Mann, 2008; Cox et al., 2011) with the following search
parameters: carbamidomethylation of cysteine and TMT modification on peptide N-termini and
lysine side chains were fixed modifications, while methionine oxidation, acetylation of N-termini of
proteins. The false discovery rate was set to 1% for positive identification of proteins and peptides
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with the help of the reversed mouse Uniprot database in a decoy approach. Copy numbers were cal-
culated as described (Wis´niewski et al., 2014) after allocating the summed MS1 intensities to the
different experimental conditions according to their fractional MS3 reporter intensities.
TCR activated CD4+ (label free)
Cell pellets were lysed and peptides generated using the SP3 method as described above, but with-
out TMT labelling. After elution with DMSO samples were fractionated by high pH reverse phase
chromatography as described above but with the following modifications; samples were loaded
onto a 2.1  150 mm Xbridge BEH130 C18 column with 3.5 mm particles (Waters) on a UltiMate
3000 HPLC (Thermo Fisher Scientific) and separated at a flow rate of 0.3 mL/min. Peptides were sep-
arated into 16 fractions which were consolidated into eight fractions. The fractions were subse-
quently dried and the peptides redissolved in 5% formic acid. LC-MS analysis was performed as
described previously (Rollings et al., 2018) with slight modifications. Samples were injected onto a
nanoscale C18 reverse-phase chromatography system (UltiMate 3000 RSLC nano, Thermo Fisher Sci-
entific) before being electrosprayed into a Orbitrap mass spectrometer (LTQ Orbitrap Velos Pro;
Thermo Fisher Scientific). The chromatography buffers used were as follows: HPLC buffer A (0.1%
formic acid), HPLC buffer B (80% acetonitrile and 0.08% formic acid), and HPLC buffer C (0.1% for-
mic acid). Peptides were loaded onto an Acclaim PepMap100 nanoViper C18 trap column (100 mm
inner diameter, 2 cm; Thermo Fisher Scientific) in HPLC buffer C with a constant flow of 5 ml/min.
After trap enrichment, peptides were eluted onto an EASY-Spray PepMap RSLC nanoViper, C18, 2
mm, 100 A˚ column (75 mm, 50 cm; Thermo Fisher Scientific) using the following buffer gradient: 2% B
(0 to 6 min), 2% to 35% B (6 to 130 min), 35% to 98% B (130 to 132 min), 98% B (132 to 152 min),
98% to 2% B (152 to 153 min), and equilibrated in 2% B (153 to 170 min) at a flow rate of 0.3 ml/min.
The eluting peptide solution was automatically electrosprayed into the Orbitrap mass spectrometer
(LTQ Orbitrap Velos Pro; Thermo Fisher Scientific) using an EASY-Spray nanoelectrospray ion source
at 50˚C and a source voltage of 1.9 kV (Thermo Fisher Scientific). The mass spectrometer was oper-
ated in positive ion mode. Full-scan MS survey spectra (mass/charge ratio, 335 to 1800) in profile
mode were acquired in the Orbitrap with a resolution of 60,000. Data were collected using data-
dependent acquisition: the 15 most intense peptide ions from the preview scan in the Orbitrap were
fragmented by collision-induced dissociation (normalized collision energy, 35%; activation Q, 0.250;
activation time, 10 ms) in the LTQ after the accumulation of 5000 ions. Precursor ion charge state
screening was enabled, and all unassigned charge states as well as singly charged species were
rejected. The lock mass option was enabled for survey scans to improve mass accuracy. MS data was
analysed as described above with the following modifications; MaxQuant software package, version
1.6.0.1. Proteins and peptides were identified using a uniport mouse canonical plus isoforms data-
base (2nd August 2018).
Single-shot proteomics on methionine deprived Th1 cells
Cell pellets were processed as described above, label free. After elution of peptides with DMSO,
samples were processed by single shot LC-MS. Analysis of peptides was performed on a Q-exactive-
HFX (Thermo Scientific) mass spectrometer coupled with a Dionex Ultimate 3000 RS (Thermo Scien-
tific). LC buffers were the following: buffer A (0.1% formic acid in Milli-Q water (v/v)) and buffer B
(80% acetonitrile and 0.08% formic acid in Milli-Q water (v/v). Aliquots of 15 mL of each sample were
loaded at 10 mL/min onto a trap column (100 mm  2 cm, PepMap nanoViper C18 column, 5 mm,
100 A˚, Thermo Scientific) equilibrated in 2% buffer B. The trap column was washed for 5 min at the
same flow rate and then the trap column was switched in-line with a Thermo Scientific, resolving C18
column (75 mm  50 cm, PepMap RSLC C18 column, 2 mm, 100 A˚). The peptides were eluted from
the column at a constant flow rate of 300 nl/min with a linear gradient from 5% buffer B to 35%
buffer B in 120 min, and then to 98% buffer B by 122 min. The column was then washed with 98%
buffer B for 15 min and re-equilibrated in 2% buffer B for 17 min. Q-exactive HFX was used in data
dependent mode. A scan cycle comprised MS1 scan (m/z range from 335 to 1800, with a maximum
ion injection time of 50 ms, a resolution of 60,000 and automatic gain control (AGC) value of 3 
106) followed by 40 sequential dependant MS2 scans (with an isolation window set to 1.4 Da, resolu-
tion at 7500, maximum ion injection time at 50 ms and AGC 1  105. MS data was analysed as
described for the label-free CD4+ TCR activated sample above. Estimates of protein copy number
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were used to calculate the fold change of protein abundance between 100 mM and 1 mM methionine
and a two-sample T test with unequal variance was performed to identify proteins significantly
changing.
Public Availability of Data
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium
data repository (https://www.ebi.ac.uk/pride/archive/login) and can be accessed with identifier
PXD012052 (for TCR activated CD4 proteome), PXD012053 (for methionine restricted Th1 prote-
ome) and PXD012058 (for naı¨ve and effector CD4 (Th1) proteomes).
Statistics
Statistical analyses were performed using Prism 4.00, GraphPad Software, or Sigma Plot (Systat). A
Shapiro-Wilk test for normality was performed to determine suitable tests for parametric or non-
parametric populations. F-tests were performed to determine equal variance of populations, other-
wise tests assuming unequal variance were performed. Multiple comparisons in one-way ANOVA
analyses were corrected for using the Holm-Sidak method. Where indicated, EC50 and R2values
were calculated with least squares fit, no constraints applied. All used tests are stated in the respec-
tive figure legends, statistical tests used for proteomics analysis are stated in the Proteomics
Materials and methods section.
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